Outset Medical Inc. Common Stock (NASDAQ: OM)
On May 5, 2022, the Company disclosed negative results for 1Q2022, which, among other things, analysts attributed to the untested nature of Tablo, its flagship product which is a dialysis machine that purifies tap water and then artificially purifies and removes toxins from the blood of patients suffering from kidney failure. On this news, shares of Outset fell more than 40% over the three trading days that followed, from a closing price of $39.94 per share on May 4, 2022, to a closing price of $23.06 per share on May 9, 2022.